Iambic Therapeutics Files Form S-1 for Nasdaq IPO Under IAM
Iambic Therapeutics filed a Form S-1 with the SEC to list on Nasdaq under IAM, backed by Nvidia and Coatue, with $207.9M in cash and clinical HER2 data.
Market-focused coverage of artificial intelligence companies, infrastructure spending, business models, and adoption. We examine the filings, financial metrics, and competitive forces behind the headlines.
Iambic Therapeutics filed a Form S-1 with the SEC to list on Nasdaq under IAM, backed by Nvidia and Coatue, with $207.9M in cash and clinical HER2 data.
Sandisk joins the S&P 100 on Monday, Sept. 21, replacing Nike as a 600% AI memory rally eclipses legacy consumer blue chips. Here is what the shift means.
Apple’s iPhone 18 Pro and Pro Max arrived in stores with a $100 price hike. But 3-week delivery delays show strong demand, lifting Q1 blended ASPs.
The Senate blocked the Ratepayer Protection Act. Here is what the clash over AI data center grid costs means for power producers and hyperscalers.
Generac stock jumped 25% after signing an $8 billion generator supply agreement with Amazon Web Services, including warrants to buy 1.69 million shares.
CoreWeave announced a $3B Rule 144A convertible senior notes offering due 2033 with capped calls to lower financing costs and fund AI infrastructure capex.
Intel and SK Hynix shares jumped over 3% after reports revealed talks to manufacture memory chips at Intel’s Ohio fab, reshaping the US semiconductor footprint.
Meta launched Meta One subscriptions across Instagram, Facebook, and WhatsApp, testing whether paid AI and creator tiers can offset soaring $140B capex.
Marvell fell 7.4% to $218.82 as AI safety warnings triggered a chip sell-off, testing whether its $2.17B data center engine can outrun fresh competition.
CrowdStrike surged 14.2% to $235.49 as an AI safety debate ignited a rotation into cybersecurity software, paired with a major HCLTech partnership expansion.